Aurobindo’s Latest Launches Include Truvada And Atripla Rivals
As Company Plans To Broaden Its Injectables Generics Portfolio In China
• By Akriti Seth
Generate a summary of this article
Listen to this article
Aurobindo has announced the launch of generic versions of Truvada, Atripla, Minocin and Gleevec in the US. As its generics business grows in the US, Europe, Canada and the rest of the world markets, Aurobindo plans to establish itself in China. The Indian pharma company has also announced its plan to commission new facilities to serve the external market.
Aurobindo is setting up a dedicated manufacturing facility for Europe and the RoW markets in Visakhapatnam India. • Source: Shutterstock
Among a wave of fresh approvals and launches in the US, Aurobindo has recently announced the launch of its generic rival to Gilead Sciences’ Truvada (emtricitabine/tenofovir disoproxil) 200mg/300mg tablets, after receiving full abbreviated new drug application approvals from the US Food and Drug Administration. The company also launched a generic of Gilead’s triple-combination Atripla (efavirenz/emtricitabine/tenofovir disoproxil) tablets in 600mg/200mg/300mg doses.
Aurobindo’s launch of Truvada comes after Teva’s and Amneal’s recent launches of its generic versions. Also see "
Stay ahead of every shift in generics and biosimilars.
Generics Bulletin brings you the latest updates that matter for the off-patent industry.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
An abbreviated licensure pathway for biologics was created by the 2009 Biologics Price Competition and Innovation Act. Biologics demonstrated to be biosimilar to or interchangeable with FDA-approved products can use the 351(k) biologics license application pathway. Biosimilars BLAs submitted under the 351(k) pathway have a 12 month user fee goal for FDA action. Updated weekly.
Amneal has marked its entry into China after receiving its first product approval in the market. Meanwhile, the firm has also outlined US approvals for two generics currently suffering from shortages.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
